Registration

The Network Genomic Medicine: Providing Structures for Personalised Cancer Therapies
Reinhard Buettner, Director, University Hospital Cologne, Germany

The Network Genomic Medicine has been established in 2010 for centralized genomic profiling of malignant tumors. In parallel a platform for innovative clinical studies has been implemented as a key element for Personalised Cancer Medicine.

Coffee and Networking in Foyer

Overview of Predictive Biomarkers of Cancer Therapy
Sherry Yang, Chief, National Clinical Target Validation Laboratory, National Cancer Institute, United States of America

The speech will briefly summarize the established biomarkers in cancer patient care, which introduces our insights into the systemic classification and clinical application of predictive/therapeutic biomarkers for targeted cancer therapy and chemotherapy.

From Sequencing to Interpretation: Bioinformatics Challenges in Next Generation Sequencing Cancer Diagnostics
Jeremy Segal, Director, University of Chicago, United States of America

Clinical laboratories aiming to establish next generation sequencing (NGS) oncology diagnostics face a daunting array of bioinformatics challenges. This lecture will review some of the major challenges at different phases of the process, from the development of NGS analysis pipelines for detection of neoplastic genomic anomalies to the implementation of systems to support clinical interpretation.

Lunch & Networking in Foyer

Poster Session in Foyer

Predicting the Predictiveness: Preclinical-to-clinical Bridging of Personalized Therapies using Translational Modeling
Arijit Chakravarty, Director, Takeda Pharmaceuticals Co Ltd, United States of America

Dealmaking in the Personalized Medicine Space: Recent Trends and Forward Prospects
Ryan Richardson, Vice President, Healthcare Investment Banking , J.P. Morgan, United Kingdom

Coffee and Networking in Foyer

Oncology and Beyond : PHC Approaches and the Benefit to Patients / Healthcare
Jean-Jacques Palombo, Senior Vice President, Roche

This talk will highlight why PHC is central to Roche’s strategy, how Roche makes PHC happen and how this concept is also being applied to high areas of unmet need beyond Oncology, such as Alzheimer’s Disease.

Patient Stratification in Neurodegenerative Diseases
Ahmed Enayetallah, Associate Medical Director for Alzheimer’s Disease, Biogen Idec, United States of America

Approaches to identify patient subgroups with shared disease characteristics by using a combination of molecular, clinical, and radiological testing to match individual patients with optimal therapy thus increasing the likelihood of favorable treatment outcome.

Point of Care Diagnostics in Personalized Medicine
Edith Schallmeiner, Global Team Director - NPT, Novartis, Switzerland

Point of care diagnostics cover a comparably small portion of existing markers, driven by the historic lack of available technologies with acceptable performance and barriers in access to POC devices. Point of care diagnostics can bring quick and reliable results not only for highly urgent tests but also for improved patient management in a decentralized care settings for a variety of complementary diagnostics.

End of Day One

Coffee and Networking in Foyer

Detection, Characterization and ex vivo Expansion of Viable CTCs
Catherine Alix-Panabières, Director of the Laboratory of Rare Human Circulating Tumor Cells, University Medical Centre of Montpellier, France

We describe, for the first time, the establishment of a permanent cell line from CTCs of one colon cancer patient. It allows a wealth of functional studies on the biology of CTCs as well as in vitro and in vivo drug testing.

Beyond Genomics For Personalized Medicine
Sam Hanash, Director, McCombs Institute for Cancer Detection and Treatment, University of Texas MD Anderson Cancer Center, United States of America

Advances in technology for cancer molecular profiling at the proteomic, immunomic and metabolomic levels provide opportunities for personalized treatment beyond tumor genomic profiling and for tailoring treatment based on expression of therapeutic targets and tumor microenvironment profiles.

Panel Discussion

• Merits of various CTC mouse traps 
• CTCs vs circulating DNA for genomic profiling
• CTCs vs microparticles/exosomes for liquid biopsy
• Functional studies for viable CTCs : in vitro and in vivo expansion of CTCs
• How to implement liquid biopsy testing into the clinic?
• Challenges of ctDNA testing

Moderator: Valerie Taly, Group Leader/Researcher, Universite Paris Descartes, France
Panelists: Klaus Pantel, Director, Institute for Tumor Biology, University of Hamburg, Germany
Catherine Alix-Panabieres, Associate Professor, University Medical Center of Montpellier, France
Samir Hanash, Director of Red & Charline McCombs Institute for the Early Detection & Treatment of Cancer, University of Texas MD Anderson Cancer Center, United States of America

Lunch & Networking in Foyer

Poster Session in Foyer

Early Engagement with Health Technology Assessment: Its Role in Evidence Generation
Ailish Higgins, Analyst, National Institute for Health and Care Excellence (NICE), United Kingdom

Early engagement with payers and health technology assessment (HTA) bodies can help to identify key clinical and economic issues in a product’s development. Thinking about solutions to these issues as early as possible can avoid unnecessary delays and inefficiencies on the road to reimbursement.

Translating Pharmacogenomics into the Clinic: A Regulatory Perspective
Theodora Katsila, Senior Research Scientist, University of Patras, Greece

The lecture will revolve around the regulatory issues and challenges to translate pharmacogenomics research findings into clinical applications to individualize drug treatment.

Close of Conference